RFA and other tumor ablation therapies are already widely used to treat liver tumors and to eliminate painful bone tumors. RFA treatment of liver tumors has been approved by the FDA for almost a decade, and some researchers recommend that RFA be the first-line treatment for tumors in that organ.
Researchers are currently studying the use of RFA and other tumor ablation methods for the following areas:
• Kidney
• Lung
• Breast
• Prostate
• Adrenal glands
The National Institutes of Health is conducting studies on RFA for the treatment of liver and kidney tumors and is also testing the efficacy of different equipment.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.